DelveInsight’s “Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the Alzheimer’s disease historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

 

Key Takeaways from the Alzheimer’s Disease Market Report

• The increase in Alzheimer’s Disease Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Alzheimer’s Disease Market is anticipated to witness growth at a considerable CAGR.
• The leading Alzheimer’s Disease Companies working in the market include Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and others.
• Promising Alzheimer’s Disease Pipeline therapies in the various stages of development include NE3107, Masitinib (AB1010), Simufilam (PTI-125), Donanemab, Hydromethylthionine mesylate (TRx0237), Semaglutide (NN6535), KFRX01 (nilotinib BE), Remternetug (LY3372993), AR1001, Tricaprilin (CER-0001), ALZ-801 (valiltramiprosate), Piromelatine (neu-P11), Fosgonimeton (ATH-1017), Buntanetap, ANAVEX2-73 (blarcamesine), AGB101 (extended-release formulation of levetiracetam), E2814, and others.
• April 2024: Alzamend Neuro Inc.- Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1/2a Study to Assess Safety, Tolerability & Efficacy of Autologous Beta-Amyloid Mutant Peptide-pulsed Dendritic Cells in Subjects With Mild-to-Moderate Alzheimer’s Dementia.
• April 2024: CHABiotech CO., Ltd- A Randomized, Double-blind, Placebo-controlled, Phase I / IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effect After Transplantation of CB-AC-02 in Patients With Alzheimer’s Disease.
• April 2024:- AbbVie- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in Subjects With Early Alzheimer’s Disease.
• April 2024:- UCB Biopharma SRL- A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period.
• April 2024:- Eli Lilly and Company- Assessment of Safety, Tolerability, and Efficacy Measured by Amyloid Reduction of LY3372993 in Early Symptomatic Alzheimer’s Disease. The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer’s disease (AD).

 

Discover which therapies are expected to grab the Alzheimer’s Disease Market Share @ Alzheimer’s Disease Market Outlook

 

Alzheimer’s Disease Overview

Alzheimer’s disease is a progressive neurological disorder that causes the brain to shrink (atrophy) and brain cells to die. It is the most common cause of dementia, a continuous decline in thinking, behavioral, and social skills that disrupts a person’s ability to function independently.

 

Alzheimer’s Disease Epidemiology Insights

The epidemiology section of Alzheimer’s Disease offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

• total Alzheimer’s Disease diagnosed prevalent cases
• Alzheimer’s Disease age-specific cases
• Alzheimer’s Disease gender-specific cases
• Alzheimer’s Disease severity-specific cases

 

Download the report to understand which factors are driving Alzheimer’s Disease Epidemiology trends @ Alzheimer’s Disease Epidemiological Insights

 

Alzheimer’s Disease Drugs Market

The Alzheimer’s Disease Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Alzheimer’s Disease signaling in Alzheimer’s Disease are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Alzheimer’s Disease Treatment Market Landscape

The Alzheimer’s Disease treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Alzheimer’s Disease has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Alzheimer’s Disease treatment guidelines, visit @ Alzheimer’s Disease Treatment Market Landscape

 

Alzheimer’s Disease Emerging Drugs Profile

• NE3107: BioVie
• Donanemab (LY3002813): Eli Lilly
• Simufilam (PTI-125): Cassava Sciences
• Hydromethylthionine mesylate/TRx0237: TauRx Therapeutics
• ALZ-801 (valiltramiprosate): Alzheon
• Fosgonimeton (ATH-1017): Athira Pharma
• Buntanetap: Annovis Bio
• ANAVEX2-73 (blarcamesine): Anavex Life Sciences

 

Alzheimer’s Disease Market Outlook

The report’s outlook on the Alzheimer’s Disease market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Alzheimer’s Disease therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Alzheimer’s Disease drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Alzheimer’s Disease market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Alzheimer’s Disease Drugs Uptake

The drug chapter of the Alzheimer’s Disease report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Alzheimer’s Disease.

 

Major Alzheimer’s Disease Companies

Several Alzheimer’s Disease Companies working in the market include Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and others.

 

Learn more about the FDA-approved drugs for Alzheimer’s Disease @ Drugs for Alzheimer’s Disease Treatment

 

Scope of the Alzheimer’s Disease Market Research Report

• Coverage- 7MM
• Alzheimer’s Disease Companies- Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc. and others
• Alzheimer’s Disease Pipeline Therapies- NE3107, Masitinib (AB1010), Simufilam (PTI-125), Donanemab, Hydromethylthionine mesylate (TRx0237), Semaglutide (NN6535), KFRX01 (nilotinib BE), Remternetug (LY3372993), AR1001, Tricaprilin (CER-0001), ALZ-801 (valiltramiprosate), Piromelatine (neu-P11), Fosgonimeton (ATH-1017), Buntanetap, ANAVEX2-73 (blarcamesine), AGB101 (extended-release formulation of levetiracetam), E2814, and others
• Alzheimer’s Disease Market Dynamics: Alzheimer’s Disease Market Drivers and Barriers
• Alzheimer’s Disease Market Access and Reimbursement, Unmet Needs and Future Perspectives

 

Discover more about Alzheimer’s Disease Drugs in development @ Alzheimer’s Disease Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Report Introduction

3. Alzheimer’s Disease Market Overview at a Glance

4. Methodology of Alzheimer’s Disease Epidemiology and Market

5. Executive Summary of Alzheimer’s Disease

6. Key events

7. Disease Background and Overview

8. Alzheimer’s Disease Patient Journey of Alzheimer’s Disease

9. Alzheimer’s Disease Epidemiology and Patient Population

10. Alzheimer’s Disease Marketed Drugs

11. Emerging Alzheimer’s Disease Therapies

12. Alzheimer’s Disease: The Seven Major Market Analysis

13. Alzheimer’s Disease KOL views

14. SWOT Analysis

15. Alzheimer’s Disease Unmet Needs

16. Alzheimer’s Disease Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/